Jasper de Boer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jasper de Boer has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Celine Vens
Department of Public Health and Primary Care, Katholieke Universiteit Leuven, Kortrijk 8500, Belgium
3 shared publications- Celine Vens
KU Leuven Campus Kulak
2 shared publications - Maan Zrein
InfYnity Biomarkers, Lyon, France
2 shared publications - Robbe D’ Hondt
KU Leuven Campus Kulak
2 shared publications - Achilleas Ghinis
Research Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium
1 shared publication - Adil Han Orta
Ghent University
1 shared publication
Latest Publications
- Open Access
- 4 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 123 (32)
A semantic-based community model for high-fidelity tuning of olfactory mixture distances
A central goal in sensory science is to establish quantitative mappings between physical stimuli and perceptual experience. Although such mappings are well defined in vision and audition, they remain elusive in olfaction, particularly for complex odor mixtures. Here, we show that perceptual distances between odor mixtures can be predicted with high fidelity and are unexpectedly well captured by a compact semantic space derived from single-molecule representations. In the Dialogue for Reverse Engineering Assessment and Methods Olfactory Mixtures Prediction Challenge, we assembled a unified dataset of odor-mixture pairs, benchmarked predictions on a hidden test set of 46 pairs, and integrated the top-performing models into a postchallenge ensemble. This model outperformed existing state-of-the-art approaches on the hidden test set, reducing RMSE by about 33% to 0.08 and increasing Pearson correlation by 53% to 0.57, and maintained strong performance on an independent validation set of 50 newly designed mixture pairs. An ensemble, retaining only olfactory semantic features for each model included, further improved predictions, raising the Pearson correlation by 7% to 0.61 on the test set and by 15% to 0.54 on the validation set. Given that semantic features were extracted from pure molecules, it suggests that mixture perception may not require fundamentally different representational principles from single-molecule olfaction. Together, these results establish a reproducible quantitative framework for olfactory mixture perception and advance efforts to measure, model, and engineer smell.
- 4 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 123 (32)
Open AccessA semantic-based community model for high-fidelity tuning of olfactory mixture distances
A central goal in sensory science is to establish quantitative mappings between physical stimuli and perceptual experience. Although such mappings are well defined in vision and audition, they remain elusive in olfaction, particularly for complex odor mixtures. Here, we show that perceptual distances between odor mixtures can be predicted with high fidelity and are unexpectedly well captured by a compact semantic space derived from single-molecule representations. In the Dialogue for Reverse Engineering Assessment and Methods Olfactory Mixtures Prediction Challenge, we assembled a unified dataset of odor-mixture pairs, benchmarked predictions on a hidden test set of 46 pairs, and integrated the top-performing models into a postchallenge ensemble. This model outperformed existing state-of-the-art approaches on the hidden test set, reducing RMSE by about 33% to 0.08 and increasing Pearson correlation by 53% to 0.57, and maintained strong performance on an independent validation set of 50 newly designed mixture pairs. An ensemble, retaining only olfactory semantic features for each model included, further improved predictions, raising the Pearson correlation by 7% to 0.61 on the test set and by 15% to 0.54 on the validation set. Given that semantic features were extracted from pure molecules, it suggests that mixture perception may not require fundamentally different representational principles from single-molecule olfaction. Together, these results establish a reproducible quantitative framework for olfactory mixture perception and advance efforts to measure, model, and engineer smell.
- 23 June 2025
- Published by Springer Nature
- p. 77-87
Multi-Event Survival-Informed Clustering for Time-to-Worsening in Multiple Sclerosis
- 23 June 2025
- Published by Springer Nature
- p. 77-87
Multi-Event Survival-Informed Clustering for Time-to-Worsening in Multiple Sclerosis
- 1 April 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (4) , 1026-1035
Association Between Thrombus Composition and Etiology in Patients With Acute Ischemic Stroke Treated by Thrombectomy
BACKGROUND: In ischemic stroke due to large vessel occlusion, cerebral blood flow is impaired by thromboemboli, which can originate from various sources in the body. A better understanding of thromboembolus composition can improve our understanding of the underlying pathophysiology and potentially guide improvement of prevention strategies. The aim of this study therefore was to perform a large-sample multi-parameter quantitative histological analysis of retrieved thromboemboli from stroke patients. METHODS: Thromboemboli (n=501) were collected from thrombectomy-treated ischemic stroke patients at AZ Groeninge Hospital (Kortrijk, Belgium) and CHU Lille (Lille, France). Stroke etiology was determined by the treating stroke specialist using the TOAST classification system (Trial of ORG 10172 in Acute Stroke Treatment). Extensive histological analysis, blinded to stroke etiology, was performed for key thrombus constituents including red blood cells (RBCs), platelets, fibrin, von Willebrand Factor, leukocytes, citrullinated histone H3 (as a marker for neutrophil extracellular traps), and extracellular (ex)DNA. Quantitative histology results were linked to etiology. RESULTS: Compared with large-artery atherosclerotic thromboemboli, cardioembolic thromboemboli contained significantly fewer RBCs and significantly more platelets, fibrin, leukocytes, and exDNA. Interestingly, cryptogenic thromboemboli contained relatively low amounts of RBCs and high amounts of platelets, similar to cardioembolic thromboemboli. A multivariable logistic regression model indicated that it is difficult to predict stroke etiology based on the individual thrombus composition. CONCLUSIONS: Based on a large sample cohort of stroke thromboemboli, we found that cardiac thromboemboli contained fewer RBCs and more platelets than atherosclerotic thromboemboli and that cryptogenic thromboemboli have a similar composition to cardiac thromboemboli in terms of RBCs and platelets.
- 1 April 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (4) , 1026-1035
Association Between Thrombus Composition and Etiology in Patients With Acute Ischemic Stroke Treated by Thrombectomy
BACKGROUND: In ischemic stroke due to large vessel occlusion, cerebral blood flow is impaired by thromboemboli, which can originate from various sources in the body. A better understanding of thromboembolus composition can improve our understanding of the underlying pathophysiology and potentially guide improvement of prevention strategies. The aim of this study therefore was to perform a large-sample multi-parameter quantitative histological analysis of retrieved thromboemboli from stroke patients. METHODS: Thromboemboli (n=501) were collected from thrombectomy-treated ischemic stroke patients at AZ Groeninge Hospital (Kortrijk, Belgium) and CHU Lille (Lille, France). Stroke etiology was determined by the treating stroke specialist using the TOAST classification system (Trial of ORG 10172 in Acute Stroke Treatment). Extensive histological analysis, blinded to stroke etiology, was performed for key thrombus constituents including red blood cells (RBCs), platelets, fibrin, von Willebrand Factor, leukocytes, citrullinated histone H3 (as a marker for neutrophil extracellular traps), and extracellular (ex)DNA. Quantitative histology results were linked to etiology. RESULTS: Compared with large-artery atherosclerotic thromboemboli, cardioembolic thromboemboli contained significantly fewer RBCs and significantly more platelets, fibrin, leukocytes, and exDNA. Interestingly, cryptogenic thromboemboli contained relatively low amounts of RBCs and high amounts of platelets, similar to cardioembolic thromboemboli. A multivariable logistic regression model indicated that it is difficult to predict stroke etiology based on the individual thrombus composition. CONCLUSIONS: Based on a large sample cohort of stroke thromboemboli, we found that cardiac thromboemboli contained fewer RBCs and more platelets than atherosclerotic thromboemboli and that cryptogenic thromboemboli have a similar composition to cardiac thromboemboli in terms of RBCs and platelets.
- 15 April 2024
- Published by Elsevier in Pattern Recognition
- Vol. 153
SurvivalLVQ: Interpretable supervised clustering and prediction in survival analysis via Learning Vector Quantization
- 15 April 2024
- Published by Elsevier in Pattern Recognition
- Vol. 153
SurvivalLVQ: Interpretable supervised clustering and prediction in survival analysis via Learning Vector Quantization
- 6 April 2023
- Published by Elsevier in Measurement
- Vol. 214
Machine learning-based orthotropic stiffness identification using guided wavefield data
- 6 April 2023
- Published by Elsevier in Measurement
- Vol. 214
Machine learning-based orthotropic stiffness identification using guided wavefield data
- Open Access
- 29 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0274553
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects
Collecting information on sustainability of immune responses after infection or vaccination is crucial to inform medical decision-making and vaccination strategies. Data on how long-lasting antibodies against SARS-COV-2 could provide a humoral and protective immunity and prevent reinfection with SARS-CoV-2 or its variants is particularly valuable. This study presents a novel method to quantitatively measure and monitor the diversity of SARS-CoV-2 specific antibody profiles over time. Serum samples from two groups were used in this study: Samples from 20 naturally infected subjects (followed for up to 1 year) and samples from 83 subjects vaccinated with one or two doses of the Pfizer BioNtech vaccine (BNT162b2/BNT162b2) (followed for up to 6 months). The Multi-SARS-CoV-2 assay, a multiparameter serology test developed for the serological confirmation of past-infections, was used to determine the reactivity of six different SARS-CoV-2 antigens. For each subject sample, 3 dilutions (1/50, 1/400 and 1/3200) were defined as an optimal set over the six antigens and their respective linear ranges. This allowed accurate quantification of the corresponding six antibodies. Nonlinear mixed-effects modelling was applied to convert intensity readings from 3 determined dilutions to a single quantification value for each antibody. Median half-life for the 20 naturally infected vs 74 vaccinated subjects (two doses) was 120 vs 50 days for RBD, 127 vs 53 days for S1 and 187 vs 86 days for S2 antibodies respectively. The newly proposed method, based on a series of a limited number of dilutions, can convert a conventional qualitative assay into a quantitative assay. This conversion helps define the sustainability of specific immune responses against each relevant viral antigen and can help in defining the protection characteristics after an infection or a vaccination.
- 29 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0274553
Open AccessA novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects
Collecting information on sustainability of immune responses after infection or vaccination is crucial to inform medical decision-making and vaccination strategies. Data on how long-lasting antibodies against SARS-COV-2 could provide a humoral and protective immunity and prevent reinfection with SARS-CoV-2 or its variants is particularly valuable. This study presents a novel method to quantitatively measure and monitor the diversity of SARS-CoV-2 specific antibody profiles over time. Serum samples from two groups were used in this study: Samples from 20 naturally infected subjects (followed for up to 1 year) and samples from 83 subjects vaccinated with one or two doses of the Pfizer BioNtech vaccine (BNT162b2/BNT162b2) (followed for up to 6 months). The Multi-SARS-CoV-2 assay, a multiparameter serology test developed for the serological confirmation of past-infections, was used to determine the reactivity of six different SARS-CoV-2 antigens. For each subject sample, 3 dilutions (1/50, 1/400 and 1/3200) were defined as an optimal set over the six antigens and their respective linear ranges. This allowed accurate quantification of the corresponding six antibodies. Nonlinear mixed-effects modelling was applied to convert intensity readings from 3 determined dilutions to a single quantification value for each antibody. Median half-life for the 20 naturally infected vs 74 vaccinated subjects (two doses) was 120 vs 50 days for RBD, 127 vs 53 days for S1 and 187 vs 86 days for S2 antibodies respectively. The newly proposed method, based on a series of a limited number of dilutions, can convert a conventional qualitative assay into a quantitative assay. This conversion helps define the sustainability of specific immune responses against each relevant viral antigen and can help in defining the protection characteristics after an infection or a vaccination.
- Open Access
- 1 November 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (11) , e0009925
A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections
Background: Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated 5 to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated cellular blood components. HTLV-associated syndromes are considered as neglected diseases for which there are no vaccines or therapies available, making it particularly important to ensure the best possible diagnosis to enable proper counselling of infected persons and avoid secondary transmission. Although high quality antibody screening assays are available, currently available confirmatory tests are costly and have variable performance, with high rates of indeterminate and non-typable results reported in many regions of the world. The objective of this project was to develop and validate a new high-performance multiplex immunoassay for confirmation and discrimination of HTLV-1 and HTLV-2 strains. Methodology/Principal findings: The multiplex platform was used first as a tool to identify suitable antigens and in a second step for assay development. With data generated on over 400 HTLV-positive blood donors sourced from USA and French blood banks, we developed and validated a high-precision interpretation algorithm. The Multi-HTLV assay demonstrated very high performance for confirmation and strain discrimination with 100% sensitivity, 98.1% specificity and 100% of typing accuracy in validation samples. The assay can be interpreted either visually or automatically with a colorimetric image reader and custom algorithm, providing highly reliable results. Conclusions/Significance: The newly developed Multi-HTLV is very competitive with currently used confirmatory assays and reduces considerably the number of indeterminate results. The multiparametric nature of the assay opens new avenues to study specific serological signatures of each patient, follow the evolution of infection, and explore utility for HTLV disease prognosis. Improving HTLV diagnostic testing will be critical to reduce transmission and to improve monitoring of seropositive patients.
- 1 November 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (11) , e0009925
Open AccessA novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections
Background: Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated 5 to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated cellular blood components. HTLV-associated syndromes are considered as neglected diseases for which there are no vaccines or therapies available, making it particularly important to ensure the best possible diagnosis to enable proper counselling of infected persons and avoid secondary transmission. Although high quality antibody screening assays are available, currently available confirmatory tests are costly and have variable performance, with high rates of indeterminate and non-typable results reported in many regions of the world. The objective of this project was to develop and validate a new high-performance multiplex immunoassay for confirmation and discrimination of HTLV-1 and HTLV-2 strains. Methodology/Principal findings: The multiplex platform was used first as a tool to identify suitable antigens and in a second step for assay development. With data generated on over 400 HTLV-positive blood donors sourced from USA and French blood banks, we developed and validated a high-precision interpretation algorithm. The Multi-HTLV assay demonstrated very high performance for confirmation and strain discrimination with 100% sensitivity, 98.1% specificity and 100% of typing accuracy in validation samples. The assay can be interpreted either visually or automatically with a colorimetric image reader and custom algorithm, providing highly reliable results. Conclusions/Significance: The newly developed Multi-HTLV is very competitive with currently used confirmatory assays and reduces considerably the number of indeterminate results. The multiparametric nature of the assay opens new avenues to study specific serological signatures of each patient, follow the evolution of infection, and explore utility for HTLV disease prognosis. Improving HTLV diagnostic testing will be critical to reduce transmission and to improve monitoring of seropositive patients.
- Open Access
- 16 April 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (11) , 1188-1197
Accurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome
Summary: Background: The development of accurate, non‐invasive markers to diagnose and stage non‐alcoholic fatty liver disease (NAFLD) is critical to reduce the need for an invasive liver biopsy and to identify patients who are at the highest risk of hepatic and cardio‐metabolic complications. Disruption of steroid hormone metabolic pathways has been described in patients with NAFLD.Aim(s): To assess the hypothesis that assessment of the urinary steroid metabolome may provide a novel, non‐invasive biomarker strategy to stage NAFLD.Methods: We analysed the urinary steroid metabolome in 275 subjects (121 with biopsy‐proven NAFLD, 48 with alcohol‐related cirrhosis and 106 controls), using gas chromatography‐mass spectrometry (GC‐MS) coupled with machine learning‐based Generalised Matrix Learning Vector Quantisation (GMLVQ) analysis.Results: Generalised Matrix Learning Vector Quantisation analysis achieved excellent separation of early (F0‐F2) from advanced (F3‐F4) fibrosis (AUC receiver operating characteristics [ROC]: 0.92 [0.91‐0.94]). Furthermore, there was near perfect separation of controls from patients with advanced fibrotic NAFLD (AUC ROC = 0.99 [0.98‐0.99]) and from those with NAFLD cirrhosis (AUC ROC = 1.0 [1.0‐1.0]). This approach was also able to distinguish patients with NAFLD cirrhosis from those with alcohol‐related cirrhosis (AUC ROC = 0.83 [0.81‐0.85]).Conclusions: Unbiased GMLVQ analysis of the urinary steroid metabolome offers excellent potential as a non‐invasive biomarker approach to stage NAFLD fibrosis as well as to screen for NAFLD. A highly sensitive and specific urinary biomarker is likely to have clinical utility both in secondary care and in the broader general population within primary care and could significantly decrease the need for liver biopsy.
- 16 April 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (11) , 1188-1197
Open AccessAccurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome
Summary: Background: The development of accurate, non‐invasive markers to diagnose and stage non‐alcoholic fatty liver disease (NAFLD) is critical to reduce the need for an invasive liver biopsy and to identify patients who are at the highest risk of hepatic and cardio‐metabolic complications. Disruption of steroid hormone metabolic pathways has been described in patients with NAFLD.Aim(s): To assess the hypothesis that assessment of the urinary steroid metabolome may provide a novel, non‐invasive biomarker strategy to stage NAFLD.Methods: We analysed the urinary steroid metabolome in 275 subjects (121 with biopsy‐proven NAFLD, 48 with alcohol‐related cirrhosis and 106 controls), using gas chromatography‐mass spectrometry (GC‐MS) coupled with machine learning‐based Generalised Matrix Learning Vector Quantisation (GMLVQ) analysis.Results: Generalised Matrix Learning Vector Quantisation analysis achieved excellent separation of early (F0‐F2) from advanced (F3‐F4) fibrosis (AUC receiver operating characteristics [ROC]: 0.92 [0.91‐0.94]). Furthermore, there was near perfect separation of controls from patients with advanced fibrotic NAFLD (AUC ROC = 0.99 [0.98‐0.99]) and from those with NAFLD cirrhosis (AUC ROC = 1.0 [1.0‐1.0]). This approach was also able to distinguish patients with NAFLD cirrhosis from those with alcohol‐related cirrhosis (AUC ROC = 0.83 [0.81‐0.85]).Conclusions: Unbiased GMLVQ analysis of the urinary steroid metabolome offers excellent potential as a non‐invasive biomarker approach to stage NAFLD fibrosis as well as to screen for NAFLD. A highly sensitive and specific urinary biomarker is likely to have clinical utility both in secondary care and in the broader general population within primary care and could significantly decrease the need for liver biopsy.